The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

i am a healthcare professional i am not a healthcare professional
Sitagliptin

Contact Us

We will be pleased to assist you Monday through Thursday from 8 AM to 8 PM ET (with the exception of holidays and certain dates around holidays).

Now, there is a fast and easy way to obtain:

  • Samples of JANUVIA
  • Access to relevant clinical articles
  • Product information from Merck
  • Educational materials for your patients
  • Answers to clinical questions about JANUVIA

You may speak directly with a Merck representative by calling 1-866-637-2562.

Request More Information

Stay informed!

Sign up now and be the first to know about Web site updates, including new clinical studies and interactive tools to support your patients and your practice. Simply enter the following information and click the I AGREE button below.

*Indicates required field

*First Name:
*Last Name:
*E-mail Address:
  Address 1:
  Address 2:
  City:
  State:
*Zip Code: -
*Professional Designation:
  Specialty:

By providing your information and clicking I AGREE below, you agree to receive additional information via e-mail or otherwise from the Merck & Co., Inc. family of companies ("Merck").

Your name, address, and any other personal information you supply will be available only to Merck and companies working for Merck or with whom Merck collaborates, who may contact you regarding product information, site enhancements, special offers, educational opportunities, and additional resources, programs, and information about Merck.

The companies working for Merck or with whom Merck collaborates have agreed to use this information only at the direction of Merck and also have agreed not to share this information with anyone else. Merck will not disclose personal information about you to anyone, except these companies or as required by law. For more information about how Merck protects personal information about you, please read Merck's Global Data Practices Commitment to Health Care Professionals and Internet Privacy Policy available at www.merck.com/policy/pdf/global_data_practices_2009.pdf and www.merck.com/about/how-we-operate/privacy/internet-privacy-policy.html.

You can manage all of your contact preferences or request that you be removed from the Merck contact list by calling 1-800-339-0400.

 

Selected Important Risk Information
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or with any other antidiabetic drug.

In clinical studies, the adverse reactions reported, regardless of investigator assessment of causality, in >5% of patients treated with JANUVIA as monotherapy and in combination therapy and more commonly than in patients treated with placebo, were upper respiratory tract infection, nasopharyngitis, and headache.

View Additional Selected Important Risk Information


Important Information

JANUVIA® (sitagliptin) tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

Before prescribing JANUVIA® (sitagliptin) tablets, please read the Prescribing Information. The Medication Guide also is available.

This site is intended for health care professionals of the United States, its territories, and Puerto Rico.

Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of  Merck & Co., Inc. All rights reserved.

DIAB-1050515-0002 12/12